Welcome to our dedicated page for Tvardi Therapeutics SEC filings (Ticker: TVRD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tvardi Therapeutics, Inc. (NASDAQ: TVRD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tvardi’s filings describe it as a Delaware corporation and a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need.
Through documents such as Form 8-K current reports, investors can review Tvardi’s announcements regarding financial results, business updates, executive and director changes, compensation arrangements, and key clinical and corporate events. Recent 8-K filings have covered quarterly results, updates on preliminary data from the REVERT IPF Phase 2 trial of TTI-101 in idiopathic pulmonary fibrosis, the availability of updated corporate presentations, and the adoption of a severance and change in control plan and retention equity awards for certain employees.
Registration statements on Form S-1/A offer additional detail on Tvardi’s business following its merger with Legacy Tvardi, the change of name from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc., and the commencement of trading on The Nasdaq Capital Market under the symbol TVRD. These filings also outline the company’s status as a smaller reporting company and its focus on STAT3-targeted clinical programs, including TTI-101 and TTI-109.
On Stock Titan, Tvardi’s SEC filings are updated as new documents are posted to EDGAR, and AI-powered summaries can help explain the key points in lengthy filings such as registration statements and current reports. Users can quickly identify items related to clinical trial disclosures, capital structure, compensation plans, and other material events, and can also monitor how Tvardi describes the progress and risks associated with its STAT3 inhibitor programs over time.
Tvardi Therapeutics reported fourth quarter and full-year 2025 results showing lower expenses and a narrower loss while advancing its STAT3 inhibitor pipeline. Research and development spending fell to $5.5 million in the quarter and $18.0 million for 2025, down from $8.6 million and $23.7 million in 2024, mainly as TTI-101 clinical costs declined.
Net loss improved to $7.3 million for the quarter and $18.2 million for the year, compared with $12.7 million and $29.4 million a year earlier. Cash, cash equivalents and short-term investments totaled $30.8 million as of December 31, 2025, and the company expects this to fund operations through key clinical readouts and into the fourth quarter of 2026.
The company highlighted upcoming milestones, including healthy volunteer data for next-generation STAT3 inhibitor TTI-109 in Q2 2026 and topline Phase 2 data for TTI-101 in hepatocellular carcinoma in the second half of 2026.
Tvardi Therapeutics files a prospectus supplement for the resale of up to 2,084,117 shares of common stock. The supplement updates the prospectus dated November 8, 2025 with information from Current Reports on Form 8-K filed December 18, 2025 and March 6, 2026. The resale shares were issued to certain selling stockholders pursuant to the Merger Agreement dated December 17, 2024.
The supplement states the Nasdaq last reported sale price was $4.02 on March 5, 2026. The supplement also attaches excerpts of two 8-Ks disclosing retention option grants, a severance and change-in-control plan, and the company’s 2026 annual meeting date and proxy submission deadlines.
Tvardi Therapeutics, Inc. has scheduled its 2026 Annual Meeting of Stockholders for June 9, 2026. Stockholder proposals seeking inclusion in the company’s proxy materials under SEC Rule 14a-8 must be received at the principal executive offices by March 16, 2026.
For other business or director nominations brought directly before the meeting under the company’s Amended and Restated Bylaws, stockholders must also submit notice by March 16, 2026. Separate notice for soliciting proxies in support of alternative director nominees in compliance with SEC Rule 14a-19 is due by April 10, 2026.
Tvardi Therapeutics, Inc. received an amended Schedule 13G filing from investor Ronald A. DePinho, reporting his beneficial ownership of the company’s common stock. As of December 31, 2025, he beneficially owned 426,190 shares, including 3,635 shares held through an entity he controls.
This stake represents 4.5% of Tvardi’s common stock, based on 9,381,344 shares outstanding as of November 10, 2025, as reported in Tvardi’s Form 10-Q. DePinho has sole voting and dispositive power over all reported shares and indicates that the holdings are not for the purpose of changing or influencing control of the company.
Tvardi Therapeutics, Inc. reported that Principal Accounting Officer Stephen Paul O'Brien received an employee stock option award on January 29, 2026. The option gives him the right to buy 15,000 shares of common stock at an exercise price of $3.90 per share.
The option vests in equal monthly installments over 48 months starting January 29, 2026, so vesting continues as long as he remains in continuous service with the company. The option expires on January 29, 2036, and all 15,000 derivative securities are reported as directly owned after this grant.
Tvardi Therapeutics, Inc. reported that its Chief Financial Officer, Avi Daniel Conn, received an employee stock option grant on January 29, 2026. The award covers 45,000 options to buy common stock at an exercise price of $3.90 per share, expiring January 29, 2036.
The options vest in equal monthly installments over 48 months, starting January 29, 2026, as long as Conn remains in continuous service through each vesting date. Following this grant, Conn holds 45,000 derivative securities directly.
Tvardi Therapeutics, Inc. reported that its Chief Medical Officer, Kauh John Saewook, M.D., received an employee stock option grant on January 29, 2026. The award covers 45,000 options to buy common stock at an exercise price of $3.90 per share.
These options vest in equal monthly installments over 48 months starting January 29, 2026, as long as the executive remains in continuous service. Following this grant, the reporting person beneficially owns 45,000 derivative securities, all held as direct ownership.
Tvardi Therapeutics, Inc. reported an insider equity award for its chief executive officer and director, Alibhai Imran Nizamudin. On January 29, 2026, he received an employee stock option covering 115,000 shares of common stock at an exercise price of $3.9 per share.
These options vest in equal monthly installments over 48 months starting January 29, 2026, contingent on his continued service with the company. Following this grant, he beneficially owns 115,000 derivative securities directly through this option award.
Tvardi Therapeutics, Inc. filed a current report to let investors know that it has released an updated corporate presentation. The new presentation, dated January 16, 2026, has been posted on the company’s website and is also included with the report as Exhibit 99.1.
The disclosure is made under Regulation FD, which is designed to ensure that all investors have access to the same information at the same time. The company also notes that this material is being furnished rather than filed, meaning it is not subject to certain liability provisions of the federal securities laws and is not automatically incorporated into other SEC filings.
Tvardi Therapeutics, Inc. approved one-time equity retention awards for key executives and adopted a new severance and change in control plan. On December 16, 2025, the Board granted options to purchase 47,500 shares to Chief Executive Officer Dr. Imran Alibhai and 17,500 shares each to Chief Medical Officer Dr. John Kauh and Chief Financial Officer Dan Conn to support performance as the company advances its TTI-101 and TTI-109 clinical programs.
The new Severance and Change in Control Plan covers certain employees, including all named executive officers, and provides cash severance, bonus-related payments, Company-paid COBRA premiums and equity vesting acceleration upon qualifying terminations. Benefits are more substantial if a termination occurs from three months before to 12 months after a change in control, including lump sum salary and bonus payments and full acceleration of unvested time-based equity awards. Outside that period, salary is paid over time and equity accelerates only to the extent it would have vested within defined future periods.